Perspective
Published on 03 Jun 2024
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
- 7,165 views
- 4 citations
Perspective
Published on 03 Jun 2024
Original Research
Published on 28 May 2024
Original Research
Published on 24 May 2024
Mini Review
Published on 22 May 2024
Mini Review
Published on 15 May 2024
Case Report
Published on 08 May 2024
Editorial
Published on 07 May 2024
Review
Published on 02 May 2024
Study Protocol
Published on 02 Apr 2024
Brief Research Report
Published on 22 Mar 2024
Original Research
Published on 18 Mar 2024
Review
Published on 04 Mar 2024
Editorial
Published on 25 Jan 2024
Systematic Review
Published on 24 Jan 2024